niacinamide has been researched along with Foot Dermatoses in 25 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Foot Dermatoses: Skin diseases of the foot, general or unspecified.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To observe the efficacy and safety of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma (HCC)." | 9.14 | [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma]. ( Chen, MS; Li, P; Lin, XJ; Xu, L; Yuan, YF; Zhang, YQ, 2009) |
| "As a group of European nurses familiar with treating patients with renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) using targeted/chemo- therapies, we aimed to review strategies for managing adverse events (AEs) associated with one targeted therapy, sorafenib." | 8.88 | Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group. ( Boers-Doets, C; Chrysou, M; Edmonds, K; Hull, D; Koldenhof, J; Molassiotis, A; Spencer-Shaw, A, 2012) |
| "Hypertension (HT) and hand-foot skin reactions (HFSR) may be related to the activity of bevacizumab and sorafenib." | 7.76 | Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. ( Baum, CE; Dahut, WL; Danesi, R; English, BC; Figg, WD; Giaccone, G; Jain, L; Kohn, EC; Kummar, S; Liewehr, D; Price, DK; Sissung, TM; Venitz, J; Venzon, D; Yarchoan, R, 2010) |
| "Sorafenib (Nexavar) is an oral multi-kinase inhibitor that targets tumor growth and angiogenesis, having encouraging efficacy and tolerability in patients with metastatic renal cell carcinoma (RCC) and other tumors." | 6.47 | Sorafenib-associated hand-foot syndrome in Japanese patients. ( Adachi, M; Akaza, H; Fukino, K; Furuse, J; Iijima, M; Minami, H; Murai, M; Naito, S; Tsukamoto, T, 2011) |
| "Sorafenib (Nexavar) is a targeted therapy acting as VEGFR and PDGFR tyrosine-kinase inhibitor that has been approved in France in the treatment of metastatic renal cell carcinoma and hepatocarcinoma." | 5.35 | [Hand-foot syndrome and sorafenib]. ( Desmedt, E; Digue, L; Milano, G; Mortier, L; Ravaud, A, 2009) |
| "To observe the efficacy and safety of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma (HCC)." | 5.14 | [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma]. ( Chen, MS; Li, P; Lin, XJ; Xu, L; Yuan, YF; Zhang, YQ, 2009) |
| "As a group of European nurses familiar with treating patients with renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) using targeted/chemo- therapies, we aimed to review strategies for managing adverse events (AEs) associated with one targeted therapy, sorafenib." | 4.88 | Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group. ( Boers-Doets, C; Chrysou, M; Edmonds, K; Hull, D; Koldenhof, J; Molassiotis, A; Spencer-Shaw, A, 2012) |
| " Our article focuses on the palmoplantar erythrodysesthesia syndrome, designated also as the hand-foot skin reaction (HFSR), which most frequently occurs in patients treated with TKI sorafenib and sunitinib." | 4.86 | [Hand-foot syndrome after administration of tyrosinkinase inhibitors]. ( Bednaríková, D; Kocák, I, 2010) |
| " This case report discusses an atypical presentation of the hand-foot syndrome in one patient treated with sorafenib." | 3.80 | Hand, foot and scrotal blisters in a patient with cancer receiving oral chemotherapy. ( Bella, A; Guerra, JR; Lolo, D; Suelves, AM, 2014) |
| "Sorafenib is a new drug, multikinase inhibitor, which has been recently approved for the treatment of metastatic renal cell carcinoma and hepatocellular carcinoma." | 3.77 | Severe sorafenib-induced hand-foot skin reaction. ( Betlloch, I; Cuesta, L; Latorre, N; Monteagudo, A; Toledo, F, 2011) |
| "Hypertension (HT) and hand-foot skin reactions (HFSR) may be related to the activity of bevacizumab and sorafenib." | 3.76 | Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. ( Baum, CE; Dahut, WL; Danesi, R; English, BC; Figg, WD; Giaccone, G; Jain, L; Kohn, EC; Kummar, S; Liewehr, D; Price, DK; Sissung, TM; Venitz, J; Venzon, D; Yarchoan, R, 2010) |
| "The multitargeted kinase inhibitors sorafenib and sunitinib have improved treatment of solid tumours including renal cell carcinoma and hepatocellular carcinoma by offering better clinical responses." | 3.75 | Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. ( Chang, SE; Choi, JH; Kang, YK; Koh, JK; Lee, JL; Lee, MW; Lee, WJ; Moon, KC, 2009) |
| "Sorafenib induces frequent cutaneous adverse events, some of which may lead to a dose reduction." | 2.73 | Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. ( Autier, J; Escudier, B; Robert, C; Spatz, A; Wechsler, J, 2008) |
| "Sorafenib (Nexavar) is an oral multi-kinase inhibitor that targets tumor growth and angiogenesis, having encouraging efficacy and tolerability in patients with metastatic renal cell carcinoma (RCC) and other tumors." | 2.47 | Sorafenib-associated hand-foot syndrome in Japanese patients. ( Adachi, M; Akaza, H; Fukino, K; Furuse, J; Iijima, M; Minami, H; Murai, M; Naito, S; Tsukamoto, T, 2011) |
| "Sorafenib (Nexavar) is a targeted therapy acting as VEGFR and PDGFR tyrosine-kinase inhibitor that has been approved in France in the treatment of metastatic renal cell carcinoma and hepatocarcinoma." | 1.35 | [Hand-foot syndrome and sorafenib]. ( Desmedt, E; Digue, L; Milano, G; Mortier, L; Ravaud, A, 2009) |
| "Sorafenib is a tyrosine kinase inhibitor prescribed primarily for the management of metastatic kidney cancer." | 1.35 | Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon? ( Chevreau, C; Delord, JP; Sibaud, V, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (56.00) | 29.6817 |
| 2010's | 10 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guerra, JR | 1 |
| Suelves, AM | 1 |
| Bella, A | 1 |
| Lolo, D | 1 |
| Lacouture, ME | 2 |
| Reilly, LM | 1 |
| Gerami, P | 1 |
| Guitart, J | 2 |
| Clark, M | 1 |
| Autier, J | 1 |
| Escudier, B | 1 |
| Wechsler, J | 1 |
| Spatz, A | 1 |
| Robert, C | 4 |
| Wu, S | 1 |
| Atkins, MB | 1 |
| Kong, HH | 3 |
| Garbe, C | 1 |
| Hauschild, A | 1 |
| Puzanov, I | 1 |
| Alexandrescu, DT | 1 |
| Anderson, RT | 1 |
| Wood, L | 1 |
| Dutcher, JP | 1 |
| Wolber, C | 1 |
| Udvardi, A | 1 |
| Tatzreiter, G | 1 |
| Schneeberger, A | 1 |
| Volc-Platzer, B | 1 |
| Azad, NS | 1 |
| Aragon-Ching, JB | 1 |
| Dahut, WL | 2 |
| Gutierrez, M | 1 |
| Figg, WD | 3 |
| Jain, L | 3 |
| Steinberg, SM | 1 |
| Turner, ML | 1 |
| Kohn, EC | 2 |
| Milano, G | 1 |
| Mortier, L | 2 |
| Digue, L | 1 |
| Desmedt, E | 1 |
| Ravaud, A | 1 |
| Xu, L | 1 |
| Li, P | 1 |
| Lin, XJ | 1 |
| Yuan, YF | 1 |
| Zhang, YQ | 1 |
| Chen, MS | 1 |
| Lee, WJ | 1 |
| Lee, JL | 1 |
| Chang, SE | 1 |
| Lee, MW | 1 |
| Kang, YK | 1 |
| Choi, JH | 1 |
| Moon, KC | 1 |
| Koh, JK | 1 |
| Echeverría, B | 1 |
| Llombart, B | 1 |
| Botella-Estrada, R | 1 |
| Guillén, C | 1 |
| Sibaud, V | 1 |
| Delord, JP | 1 |
| Chevreau, C | 2 |
| Lipworth, AD | 1 |
| Zhu, AX | 1 |
| Gardner, ER | 1 |
| Chernick, MS | 1 |
| Rosmorduc, O | 1 |
| Dielenseger, P | 1 |
| Ederhy, S | 1 |
| Goldwasser, F | 1 |
| Grange, JD | 1 |
| Neidhardt-Berard, ME | 1 |
| Scotté, F | 1 |
| Seitz, JF | 1 |
| Degen, A | 1 |
| Alter, M | 1 |
| Schenck, F | 1 |
| Satzger, I | 1 |
| Völker, B | 1 |
| Kapp, A | 1 |
| Gutzmer, R | 1 |
| Sissung, TM | 1 |
| Danesi, R | 1 |
| Kummar, S | 1 |
| Venzon, D | 1 |
| Liewehr, D | 1 |
| English, BC | 1 |
| Baum, CE | 1 |
| Yarchoan, R | 1 |
| Giaccone, G | 1 |
| Venitz, J | 1 |
| Price, DK | 1 |
| Bednaríková, D | 1 |
| Kocák, I | 1 |
| Iijima, M | 1 |
| Fukino, K | 1 |
| Adachi, M | 1 |
| Tsukamoto, T | 1 |
| Murai, M | 1 |
| Naito, S | 1 |
| Minami, H | 1 |
| Furuse, J | 1 |
| Akaza, H | 1 |
| Cuesta, L | 1 |
| Betlloch, I | 1 |
| Toledo, F | 1 |
| Latorre, N | 1 |
| Monteagudo, A | 1 |
| Edmonds, K | 1 |
| Hull, D | 1 |
| Spencer-Shaw, A | 1 |
| Koldenhof, J | 1 |
| Chrysou, M | 1 |
| Boers-Doets, C | 1 |
| Molassiotis, A | 1 |
| Martínez-Morán, C | 1 |
| Nájera, L | 1 |
| Ruiz-Casado, AI | 1 |
| Romero-Maté, A | 1 |
| Espinosa, P | 1 |
| Meseguer-Yebra, C | 1 |
| Córdoba, S | 1 |
| Borbujo, JM | 1 |
| Yang, CH | 1 |
| Lin, WC | 1 |
| Chuang, CK | 1 |
| Chang, YC | 1 |
| Pang, ST | 1 |
| Lin, YC | 1 |
| Kuo, TT | 1 |
| Hsieh, JJ | 1 |
| Chang, JW | 1 |
| Auxilia, ST | 1 |
| Hill, PB | 1 |
| Thoday, KL | 1 |
| Chavez, E | 1 |
| Kratzer, FH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Label, Pilot Study Evaluating the Effect of Topical Sildenafil as Pre-Treatment for Hand-Foot Skin Reaction[NCT03229512] | Early Phase 1 | 2 participants (Actual) | Interventional | 2017-04-11 | Completed | ||
| The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction in Patients With Korean Hepatocellular Carcinoma Patients: Multicenter, Prospective Randomized Double-Blind Controlled Study[NCT03212625] | Phase 4 | 288 participants (Actual) | Interventional | 2016-01-28 | Completed | ||
| A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer[NCT00090545] | Phase 2 | 46 participants (Actual) | Interventional | 2004-09-01 | Completed | ||
| Re-validating Prophylactic Efficacy of Urea-based Cream on Sorafenib-induced Hand-foot Skin Reaction in Patients With Advanced Hepatocellular Carcinoma[NCT04568330] | 129 participants (Actual) | Interventional | 2014-03-21 | Completed | |||
| "Evaluation of the Restorative Efficacy of the Cosmetic Product Onco-Repair vs. Placebo on Grade 2 Hand Foot Syndrome Induced by Targeted Therapies or Conventional Chemotherapy. Randomized, Multicentre, Double Blind, Controlled Study Versus Placebo."[NCT03612011] | Phase 3 | 72 participants (Actual) | Interventional | 2018-07-12 | Completed | ||
| Phase II Study of BAY 43-9006 in Japanese Patients With Renal Cell Carcinoma[NCT00661375] | Phase 2 | 131 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Geometric mean exposure for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, and 24 hours post-dose
| Intervention | mg/L.h (Geometric Mean) |
|---|---|
| First Stage - Disease Progression | 9.76 |
| Second Stage - Increased Accrual | 18.63 |
Plasma concentration-time profile for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, AND 24 hours post dose
| Intervention | mg/L (Mean) |
|---|---|
| First Stage - Disease Progression | 1.28 |
| Second Stage - Increased Accrual | 2.57 |
Time from treatment start date until date of death or date last known alive. (NCT00090545)
Timeframe: Time from treatment start date until date of death or date last known alive, approximately 18.3 months.
| Intervention | Months (Median) |
|---|---|
| First Stage - Disease Progression | 18 |
| Second Stage - Increased Accrual | 18.3 |
Here is the number of participants with adverse events. For the detailed list of adverse events, see the adverse event module. (NCT00090545)
Timeframe: Date treatment consent signed to date off study, approximately 49 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| First Stage - Disease Progression | 22 |
| Second Stage - Increased Accrual | 23 |
Determine whether BAY 43-9006 when used to treat metastatic prostate cancer is associated with having 50% of Patients Progression Free at 4 Months by clinical, radiographic, and prostatic specific antigen (PSA)criteria. (NCT00090545)
Timeframe: 4 months
| Intervention | months (Median) |
|---|---|
| First Stage - Disease Progression | 1.83 |
| Second Stage - Increased Accrual | 3.7 |
Time to maximum concentration for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, and 24 hours post-dose
| Intervention | hours (Median) |
|---|---|
| First Stage - Disease Progression | 0.68 |
| Second Stage - Increased Accrual | 8 |
Overall response was evaluated by the RECIST. Complete Response (CR) is the disappearance of all target lesions. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. (NCT00090545)
Timeframe: Every 2 cycles (1 cycle = 28 days)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Response | Partial Response | Progressive Disease | Stable Disease | |
| First Stage - Disease Progression | 0 | 0 | 8 | 0 |
| Second Stage - Increased Accrual | 0 | 1 | 13 | 10 |
7 reviews available for niacinamide and Foot Dermatoses
| Article | Year |
|---|---|
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Topics: Benzenesulfonates; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Neoplasms; Niacinamide; Phenyl | 2008 |
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Topics: Benzenesulfonates; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Neoplasms; Niacinamide; Phenyl | 2008 |
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Topics: Benzenesulfonates; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Neoplasms; Niacinamide; Phenyl | 2008 |
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Topics: Benzenesulfonates; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Neoplasms; Niacinamide; Phenyl | 2008 |
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Foot Dermatoses; Hand Dermatoses | 2009 |
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Foot Dermatoses; Hand Dermatoses | 2009 |
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Foot Dermatoses; Hand Dermatoses | 2009 |
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Foot Dermatoses; Hand Dermatoses | 2009 |
[Use of sorafenib in patients with hepatocellular or renal carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical | 2010 |
The hand-foot-syndrome associated with medical tumor therapy - classification and management.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dermatolog | 2010 |
[Hand-foot syndrome after administration of tyrosinkinase inhibitors].
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; | 2010 |
Sorafenib-associated hand-foot syndrome in Japanese patients.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase | 2011 |
Sorafenib-associated hand-foot syndrome in Japanese patients.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase | 2011 |
Sorafenib-associated hand-foot syndrome in Japanese patients.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase | 2011 |
Sorafenib-associated hand-foot syndrome in Japanese patients.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase | 2011 |
Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical | 2012 |
2 trials available for niacinamide and Foot Dermatoses
| Article | Year |
|---|---|
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; | 2008 |
[Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Female; | 2009 |
16 other studies available for niacinamide and Foot Dermatoses
| Article | Year |
|---|---|
Hand, foot and scrotal blisters in a patient with cancer receiving oral chemotherapy.
Topics: Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Aged; Blister; Carcinoma, He | 2014 |
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinom | 2008 |
Reader seeks clarification on hand-foot skin reaction.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Information Services; Drug Labeling; Foot Dermatoses; | 2008 |
Perforating folliculitis, angioedema, hand-foot syndrome--multiple cutaneous side effects in a patient treated with sorafenib.
Topics: Aged; Angioedema; Antineoplastic Agents; Benzenesulfonates; Diagnosis, Differential; Drug Eruptions; | 2009 |
Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2009 |
[Hand-foot syndrome and sorafenib].
Topics: Benzenesulfonates; Dermatology; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Kidney Neo | 2009 |
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Benzenesulfon | 2009 |
[Palmoplantar cutaneous reaction to sorafenib].
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; | 2009 |
Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Foot Dermatoses; Hand Dermatoses; H | 2009 |
Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction.
Topics: Antineoplastic Agents; Benzenesulfonates; Chromatography, High Pressure Liquid; Drug Eruptions; Fema | 2010 |
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
Severe sorafenib-induced hand-foot skin reaction.
Topics: Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Hepatocellular; Clobetasol; Dis | 2011 |
Interstitial granulomatous drug reaction to sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Foot Dermatoses; Granuloma; Hand Der | 2011 |
Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Benzenesulfonates; Blister; Carcinoma, Renal Cell; Drug Eruptions; Female; | 2008 |
Canine symmetrical lupoid onychodystrophy: a retrospective study with particular reference to management.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Azathioprine; Dermatitis; Dog Diseases; Do | 2001 |
Effect of diet on foot pad dermatitis in poults.
Topics: Aminobutyrates; Animal Feed; Animals; Betaine; Biotin; Body Weight; Chickens; Cystine; Diet; Ethers; | 1974 |